B of A Securities analyst Jason Zemansky downgrades Esperion Therapeutics (NASDAQ:ESPR) from Neutral to Underperform and lowers the price target from $2.9 to $2.5.
B of A Securities Downgrades Esperion Therapeutics to Underperform, Lowers Price Target to $2.5
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.